Revelation Biosciences Expands Acute Kidney Injury Advisory Board

SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced the expansion of its Acute Kidney Injury (AKI) Advisory Board, with the addition of two new members, Dr. Peter Pickkers and Dr. Lui Forni, ahead of its upcoming Phase 2/3 clinical trial. The distinguished panel comprises internationally recognized nephrologists and critical care physicians who will guide the company's clinical strategy, monitor trial progress, and advance Gemini as a treatment for AKI.